{"entity":{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","aka":["CAMPFIRE"],"tldr":"A phase 2 trial of Abemaciclib and Temozolomide in ewing sarcoma, run by Eli Lilly and Company, active and no longer recruiting.","summary":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma is a phase 2 interventional study registered as NCT05440786 by Eli Lilly and Company, with 46 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2025-01-15. Interventions recorded: Abemaciclib, Irinotecan and Temozolomide. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05440786","url":"https://clinicaltrials.gov/study/NCT05440786"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ewing-sarcoma"],"sections":[],"technologies":["cdk46-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["abemaciclib","temozolomide"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05440786","phase":"2","setting":"A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma","sponsor":"Eli Lilly and Company","started":"2022-09-20","startedType":"actual","yearReported":2026,"enrolled":46,"enrolledBasis":"registry","outcomes":[{"endpoint":"PFS Assessed by BIRC by Frequentist Analysis","primary":true,"unit":"months","arms":[{"name":"Abemaciclib + Irinotecan +Temozolomide","n":30,"value":2.79,"note":"95% CI 1.74 to 13.32; Figures from the ClinicalTrials.gov results section (first posted 2026-03-12), not from a publication"},{"name":"Irinotecan +Temozolomide","n":16,"value":2.89,"note":"95% CI 1.25 to 5.13"}],"hr":0.639,"ci":[0.282,1.449],"p":"0.281","source":"https://clinicaltrials.gov/study/NCT05440786?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Abemaciclib + Irinotecan +Temozolomide","n":30,"value":21.21,"note":"95% CI 9.17 to NA; Figures from the ClinicalTrials.gov results section (first posted 2026-03-12), not from a publication"},{"name":"Irinotecan +Temozolomide","n":16,"value":6.94,"note":"95% CI 5.13 to NA"}],"hr":0.667,"ci":[0.255,1.745],"p":"0.406","source":"https://clinicaltrials.gov/study/NCT05440786?tab=results"}]},"route":"/trials/nct05440786/","neighbours":{"cancer":[{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}